MDXXF (Pharmala Biotech Holdings) Other Current Receivables: $0.20 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXXF Pharmala Biotech Holdings Inc MDXXF
33 GF Score
Price $0.14
GF Value $0.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Other Current Receivables?

Pharmala Biotech Holdings MDXXF -1.43% 33 Other Current Receivables is $0.20 Mil as of May. 2026. GuruFocus rates MDXXF with a GF Score™ of 33/100 and a GF Value™ of $0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Pharmala Biotech Holdings's Other Current Receivables for the quarter that ended in May. 2026 was $0.20 Mil.

Pharmala Biotech Holdings's quarterly Other Current Receivables declined from Nov. 2025 ($0.13 Mil) to Feb. 2026 ($0.13 Mil) but then increased from Feb. 2026 ($0.13 Mil) to May. 2026 ($0.20 Mil).

Pharmala Biotech Holdings's annual Other Current Receivables declined from Aug. 2023 ($0.06 Mil) to Aug. 2024 ($0.01 Mil) but then increased from Aug. 2024 ($0.01 Mil) to Aug. 2025 ($0.13 Mil).

Pharmala Biotech Holdings Other Current Receivables Related Terms

Pharmala Biotech Holdings Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings Other Current Receivables Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Other Current Receivables
0.05 0.02 0.06 0.01 0.13

Pharmala Biotech Holdings Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.13 0.13 0.13 0.20
MDXXF
33GF Score
Pharmala Biotech Holdings Inc MDXXF
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.20 Mil mean?
Pharmala Biotech Holdings (MDXXF) has a Other Current Receivables of $0.20 Mil as of May. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' Other Current Receivables too high?
Pharmala Biotech Holdings' current Other Current Receivables is $0.20 Mil. Overall, Pharmala Biotech Holdings has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Other Current Receivables compare to VRTX and REGN?
Pharmala Biotech Holdings' Other Current Receivables of $0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current Other Current Receivables is $0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.17, compared to a current price of $0.14 — trading 19% below its estimated fair value. The current Other Current Receivables is $0.20 Mil. Pharmala Biotech Holdings' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Other Current Receivables is $0.20 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.14 is trading 19% below its estimated GF Value™ of $0.17. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • Other Current Receivables: $0.20 Mil
  • GF Value™: $0.17 vs. price of $0.14 (19% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
33GF Score

Get the complete analysis for MDXXF

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price
$0.17
GF Value